ZVRA — ZEVRA THERAPEUTICS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1434647 ·
Last close
$9.40
Market Cap
$559.34M
52W High
$15.03
52W Low
$8.01
ADV30
977,693
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 37,756,000 35,962,000 11,580,000 19,208,000 313,575,000 122,148,000 74,652,000
Jun 2026 39,663,000 38,138,000 16,777,000 8,752,000 302,712,000 145,321,000 85,060,000
Mar 2026 36,220,000 34,323,000 8,832,000 37,890,000 278,579,000 95,595,000 72,775,000
Dec 2025 34,125,000 32,605,000 9,315,000 12,165,000 284,731,000 62,406,000 130,074,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$38,737,000
Investing CF
$76,445,000
Financing CF
$-47,122,000
CapEx
$-1,044,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.99
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-356,210,000
Inventory
$3,070,000
Receivables
$19,943,000
ST Investments
$73,420,000
EBIT TTM
$93,641,000
Pretax Income TTM
$89,982,000
Interest Exp TTM
$3,659,000
Analysts
8

Yahoo Snapshot (yfinance, live)

Total Revenue
$147,764,000
EBITDA
$47,976,000
Free Cash Flow
$51,229,124
Enterprise Value
$495,318,560
Total Cash
$195,568,000
Total Debt
$1,228,000
Shares Out
59,504,621
Trailing EPS
$1.22
Book Value
$4.02
ROE
41.9%
ROA
10.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 106,470,000 -4,233,000 83,229,000 284,731,000 130,074,000 154,657,000 -1,598,000
Dec 2024 23,612,000 -87,003,000 -105,511,000 178,127,000 138,461,000 39,666,000 -69,665,000
Dec 2023 27,461,000 -49,604,000 -46,049,000 172,327,000 110,463,000 61,864,000 -33,535,000
Dec 2022 10,161,000 -24,902,000 -26,772,000 115,340,000 40,220,000 75,120,000 -18,717,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$136,071,000
NetIncome TTM
$58,263,000
OpCashFlow TTM
—
Assets (Latest)
$302,712,000
Forward EPS
$1.05

Max Pain — expiry 2027-02-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $12.00 · spot: $9.28 · call volume: 618 · put volume: 2,046
Expected Move to 2027-02-19: ±$2.88 (31.03%) — implied range $6.40 – $12.16 · ATM straddle on $9.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
WVE Wave Life Sciences, Inc. $560.13M $2.84 —
ANL Adlai Nortye Group Ltd. $556.80M $9.48 —
AVBP ArriVent BioPharma, Inc. $552.92M $10.69 —
CLYM Climb Bio, Inc. $574.46M $9.78 —
ACRS Aclaris Therapeutics, Inc. $536.11M $3.38 —

News headlines (Yahoo Finance, 1h cache)

Zevra Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
2026-11-18 12:30 · Yahoo
Zevra’s Lead Drug Faces Potential European Setback – ZVRA Stock Heads For Worst Day In A Month
2026-11-13 13:32 · Yahoo
Zevra Therapeutics Announces Final CHMP Opinion on Arimoclomol for the Treatment of Niemann-Pick Disease Type C (NPC) in the European Union
2026-11-13 11:26 · Yahoo
Wall Street Analysts Believe Zevra Therapeutics (ZVRA) Could Rally 117.86%: Here's is How to Trade
2026-11-09 13:55 · Yahoo
Zevra (ZVRA) Q3 2026 Earnings Call Transcript
2026-11-04 16:16 · Yahoo
Zevra Therapeutics, Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
Zevra Therapeutics Inc (ZVRA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 45% as MIPLYFFA ...
2026-11-04 07:10 · Yahoo
Zevra Therapeutics Q3 Earnings Call Highlights
2026-11-03 23:14 · Yahoo
Zevra Therapeutics (ZVRA) Q3 Earnings and Revenues Beat Estimates
2026-11-03 21:50 · Yahoo
Zevra Therapeutics: Q3 Earnings Snapshot
2026-11-03 21:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.